Alpha Cognition Inc. is a commercial-stage biopharmaceutical company focused on developing innovative treatments for neurodegenerative diseases, including Alzheimer’s disease and cognitive impairment associated with mild traumatic brain injury (mTBI). In July 2024, the U.S. FDA approved its New Drug Application for ZUNVEYL® (benzgalantamine), an oral tablet formulation for mild-to-moderate Alzheimer’s disease, marking a significant milestone that shifts the company’s emphasis toward commercial manufacturing and sales. Beyond this flagship product, Alpha Cognition Inc. maintains three preclinical programs: ZUNVEYL combined with memantine for moderate-to-severe Alzheimer’s, a sublingual formulation of ALPHA-1062, and an intranasal version targeting mTBI-related cognitive issues. The company operates within the pharmaceuticals sector, addressing critical unmet needs where treatment options remain limited. Led by experienced executives in neuroscience commercialization, finance, and scientific development, Alpha Cognition Inc. plays a vital role in advancing therapies for conditions affecting millions worldwide, contributing to the broader effort to transform neurodegenerative disease management.